Clinical Trial Update: Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the long-term walking effect of ticagrelor in subjects with peripheral arterial disease who underwent EVR; the study was terminated b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Peripheral Artery Disease (PAD) | Phase 2 | Status: TERMINATED | Results posted: 2017-06-14